Clinical Trial Update: IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial of IvaBradinE for diabetic kidney disease in type 2 diabetes patients with coronary heart disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease

Drugs mentioned

• IVABRADINE

Snippet

Sponsor: Nanjing First Hospital, Nanjing Medical University | Conditions: Diabetic Kidney Disease | Phase 3 | Status: WITHDRAWN